Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1471

Sort by

Sort Order Select

Journal Articles

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Blood (2021) 138 (4): 331–343.

https://doi.org/10.1182/blood.2020010438

Published: 2021

Includes: Supplemental data

Journal Articles

Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations

Wenjian Yang, Meenakshi Devidas, Yiwei Liu, Colton Smith, Yunfeng Dai, Naomi Winick, Stephen P. Hunger, Mignon L. Loh, Elizabeth A. Raetz, Eric C. Larsen, William L. Carroll, Stuart S. Winter, Kimberly P. Dunsmore, Leonard A. Mattano, Jr, Mary V. Relling, Seth E. Karol

Blood (2021) 137 (11): 1550–1552.

https://doi.org/10.1182/blood.2020008471

Published: 2021

Includes: Supplemental data

Journal Articles

Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia

Lili Song, Bo Yu, Yi Yang, Jianwei Liang, Yingwen Zhang, Lixia Ding, Tianyi Wang, Xinyu Wan, Xiaomin Yang, Jingyan Tang, Shengyue Wang, Benshang Li, Yanxin Li, Haizhong Feng

Blood (2021) 137 (9): 1181–1191.

https://doi.org/10.1182/blood.2020005622

Published: 2021

Includes: Supplemental data

Journal Articles

Enshaei A, O’Connor D, Bartram J, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135(17):1438-1446.

Blood (2020) 136 (12): 1468.

https://doi.org/10.1182/blood.2020008578

Published: 2020

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Blood (2020) 135 (17): 1438–1446.

https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia

Malwine J. Barz, Jana Hof, Stefanie Groeneveld-Krentz, Jui Wan Loh, Annabell Szymansky, Kathy Astrahantseff, Arend von Stackelberg, Hossein Khiabanian, Adolfo A. Ferrando, Cornelia Eckert, Renate Kirschner-Schwabe

Blood (2020) 135 (12): 921–933.

https://doi.org/10.1182/blood.2019002499

Published: 2020

Includes: Supplemental data

Journal Articles

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Martin Stanulla, Hélène Cavé, Anthony V. Moorman

Blood (2020) 135 (4): 252–260.

https://doi.org/10.1182/blood.2019000813

Published: 2020

Journal Articles

Beat pediatric ALL MRD: CD28 CAR T and transplant

Marco Ruella, Frederick L. Locke

Blood (2019) 134 (26): 2333–2335.

https://doi.org/10.1182/blood.2019003821

Published: 2019

Journal Articles

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

Ruiqi Chen, MSc, Xing Liu, PharmD, Solaf Kanfar, MD, Dawn Maze, MDFRCPC,MSc, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, Anna Xu, Umberto Falcone, MD, Jack Seki, PharmD, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 1303.

https://doi.org/10.1182/blood-2019-124117

Published: 2019

Journal Articles

Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium

Ross Mangum, MD, Tiffany M. Chambers, MPH, Andria Stevens, MPH, Robert C. Lynch, MD, Evanette Burrows, MPH, Tamara P. Miller, MDMSc, Kelly D Getz, Richard Aplenc, MD PhD, Philip J. Lupo, PhD MPH, Maria Monica J. Gramatges, MD PhD, Michael E. Scheurer, PhD MPH, Karen R. Rabin, MD PhD

Blood (2019) 134 (Supplement_1): 1304.

https://doi.org/10.1182/blood-2019-130351

Published: 2019

Journal Articles

Diplotype Analysis of NUDT15 Variants By Targeted Sequencing in Pediatric Acute Lymphoblastic Leukemia

Chih-Hsiang Yu, Ya-Hsuan Chang, PhD, Wen-Chien Chou, MD, PhD, Der-Shiun Wang, MD, Shu-Wha Lin, PhD, Hsuan-Yu Chen, PhD, Yung-Li Yang, MD PhD

Blood (2019) 134 (Supplement_1): 1305.

https://doi.org/10.1182/blood-2019-124053

Published: 2019

Journal Articles

Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Blood (2019) 134 (Supplement_1): 1306.

https://doi.org/10.1182/blood-2019-127091

Published: 2019

Journal Articles

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Bernice Oh, MBBS, MRCP, Shawn Lee, MD, Zelia Seeto, Germaine Liew, Bsc, Edwynn Chiew, MBBS, Zhi Wei Chen, Bsc, Yiong Huak Chan, PhD, Jing Jia Eng, Bsc, Koon Mian Foo, Bsc, Ching Mei Joyce Lam, MD, Ah Moy Tan, MD, Allen Eng Juh Yeoh, MD

Blood (2019) 134 (Supplement_1): 1307.

https://doi.org/10.1182/blood-2019-122098

Published: 2019

Journal Articles

Outcomes in Older Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Linker Protocol at a Single Center Institution

Cindy Lynn Hickey, MDFRCPC, David Conrad, MD PhD, Stephen Couban, MDBSc

Blood (2019) 134 (Supplement_1): 1308.

https://doi.org/10.1182/blood-2019-121336

Published: 2019

Journal Articles

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Atte Nikkilä, MD, Olli Lohi, MD PhD, Ólafur Gísli Jónsson, MD PhD, Bendik Lund, MD PhD, Jonas Abrahamsson, Goda Elizabeta Vaitkeviciene, MD PhD, Kaie Pruunsild, MD, Mats Heyman, MD PhD, Hanne Vibeke Marquart, MD PhD, Kim Vettenranta, MD PhD, Kjeld Schmiegelow, MD PhD

Blood (2019) 134 (Supplement_1): 742.

https://doi.org/10.1182/blood-2019-122914

Published: 2019

Journal Articles

Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia

Clara Reglero, PhD, Dieck L. Chelsea, PhD, Jui Wan Loh, Hossein Khiabanian, PhD, Adolfo Ferrando, MD, PhD

Blood (2019) 134 (Supplement_1): 728.

https://doi.org/10.1182/blood-2019-128615

Published: 2019

Journal Articles

NUDT15 Genetic Variation Is the Strongest Predictive Marker of Tolerance to 6-Mercaptopurine in Japanese Childhood ALL Patients: A Genome-Wide Association Study

Yoichi Tanaka, PhD, Kevin Y Urayama, PhD MPH, Makiko Mori, MD, Daisuke Hasegawa, MD PhD, Yasushi Noguchi, MD, Masakatsu Yanagimachi, MD PhD, Dai Keino, MD PhD, Setsuo Ota, MD PhD, Koshi Akahane, MD PhD, Mayumi Hangai, MD, Takahisa Kawaguchi, Masatoshi Takagi, MD PhD, Katsuyoshi Koh, MD, Fumihiko Matsuda, Atsushi Manabe, MD PhD

Blood (2019) 134 (Supplement_1): 1347.

https://doi.org/10.1182/blood-2019-129440

Published: 2019

Journal Articles

Association of Germline Variants of TCF3 and PAX5 with Pediatric Acute Lymphoblastic Leukemia Development

Satoshi Miyamoto, MD, Takuya Naruto, MD PhD, Tomohiro Morio, MD PhD, Kevin Y Urayama, PhD MPH, Atsushi Manabe, MD PhD, Masatoshi Takagi, MD PhD

Blood (2019) 134 (Supplement_1): 1466.

https://doi.org/10.1182/blood-2019-128313

Published: 2019

Journal Articles

Germline Gene Aberrations Are Common in High-Risk Adult and Pediatric Acute Lymphoblastic Leukemia Patients

Suvi Douglas, MSc, Atte Lahtinen, BM, Jessica Koski, BSc, Lilli Leimi, MD, Mikko A Keränen, MD PhD, Kimmo Porkka, Caroline A Heckman, PhD, Kirsi Jahnukainen, MD PhD, Outi Kilpivaara, PhD, Ulla Wartiovaara-Kautto, MD PhD

Blood (2019) 134 (Supplement_1): 1472.

https://doi.org/10.1182/blood-2019-126657

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations

Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia

Enshaei A, O’Connor D, Bartram J, et al. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood. 2020;135(17):1438-1446.

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia

IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?

Beat pediatric ALL MRD: CD28 CAR T and transplant

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium

Diplotype Analysis of NUDT15 Variants By Targeted Sequencing in Pediatric Acute Lymphoblastic Leukemia

Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Successful Toxicity Reduction in Ma-Spore ALL 2010 in Standard/Intermediate Risk Childhood ALL: Replacing Cytarabine/Doxorubicin with More Vincristine and L-Asparaginase during Consolidation and Delayed Intensification

Outcomes in Older Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Linker Protocol at a Single Center Institution

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia

NUDT15 Genetic Variation Is the Strongest Predictive Marker of Tolerance to 6-Mercaptopurine in Japanese Childhood ALL Patients: A Genome-Wide Association Study

Association of Germline Variants of TCF3 and PAX5 with Pediatric Acute Lymphoblastic Leukemia Development

Germline Gene Aberrations Are Common in High-Risk Adult and Pediatric Acute Lymphoblastic Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only